Want to see INKT full AI Analyst Report?
INKT Stock Chart & Stats
$11.38
$0.71(6.85%)
At close: 4:00 PM EDT
$11.38
$0.71(6.85%)
Day’s Range― - ―
52-Week Range$8.48 - $16.93
Previous CloseN/A
Volume20.36K
Average Volume (3M)19.20K
Market Cap
$48.02M
Enterprise Value$49.92M
Total Cash (Recent Filing)$8.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Nov 13, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.39
Shares Outstanding5,103,002
10 Day Avg. Volume15,871
30 Day Avg. Volume19,195
Financial Highlights & Ratios
PEG Ratio-3.68
Price to Book (P/B)-3.35
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-323.41
Enterprise Value/Ebitda-4.17
Forecast
1Y Price Target
$35.00Price Target Upside207.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Off-the-shelf Platform DifferentiationThe off-the-shelf design could simplify treatment delivery compared with patient-specific cell therapies by reducing manufacturing and preparation requirements. Its inventory-based model and ability to deploy without apheresis or HLA matching may support broader clinical access and scalable development if efficacy is confirmed.
Randomized Phase 2 ExecutionMoving into a randomized Phase 2 study creates a more rigorous path to determine whether agenT-797 delivers benefits beyond supportive care or patient selection. U.S. expansion and a planned readout provide defined development milestones that could materially clarify the program’s clinical and regulatory potential.
Multi-indication Translational PotentialClinical activity in heavily pretreated gastroesophageal cancer supports the possibility that MiNK’s iNKT approach may have utility beyond a single disease setting. Evidence across oncology and ARDS could diversify the development portfolio and increase the strategic value of the underlying cell-therapy platform.
Bears Say
No Operating Revenue And Persistent LossesThe absence of reported product revenue means MiNK remains dependent on clinical progress, partnerships, or financing rather than recurring commercial operations. Persistent net losses and negative gross profit indicate that the current business model has not yet demonstrated sustainable economics or a near-term path to profitability.
Negative Equity And Solvency PressurePersistently negative equity reflects the cumulative effect of operating losses and weakens the company’s financial cushion. Although reported debt is modest, the deficit increases reliance on external capital and limits flexibility to fund clinical development, absorb setbacks, or sustain operations without additional financing.
Severe Cash-burn And Funding DependenceContinued cash consumption leaves MiNK reliant on financing, partnerships, or future program revenue to advance its pipeline. The unusually large TTM operating outflow relative to historical scale heightens funding risk, while additional capital could dilute shareholders or constrain the pace of pivotal clinical development.
MiNK Therapeutics News
INKT FAQ
What was MiNK Therapeutics’s price range in the past 12 months?
MiNK Therapeutics lowest stock price was $8.48 and its highest was $16.93 in the past 12 months.
What is MiNK Therapeutics’s market cap?
MiNK Therapeutics’s market cap is $48.02M.
When is MiNK Therapeutics’s upcoming earnings report date?
MiNK Therapeutics’s upcoming earnings report date is Nov 13, 2026 which is in 25 days.
How were MiNK Therapeutics’s earnings last quarter?
MiNK Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.6 by -$0.02.
Is MiNK Therapeutics overvalued?
According to Wall Street analysts MiNK Therapeutics’s price is currently Undervalued.
Does MiNK Therapeutics pay dividends?
MiNK Therapeutics does not currently pay dividends.
What is MiNK Therapeutics’s EPS estimate?
MiNK Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does MiNK Therapeutics have?
MiNK Therapeutics has 5,103,002 shares outstanding.
What happened to MiNK Therapeutics’s price movement after its last earnings report?
MiNK Therapeutics reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.6. Following the earnings report the stock price went down -3.169%.
Which hedge fund is a major shareholder of MiNK Therapeutics?
Currently, no hedge funds are holding shares in INKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MiNK Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (207.56% Upside)
$35.00 (207.56% Upside)
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.9%
Last 30 Days ▲ 17.5%
Last 30 Days ▲ 17.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.83%
12-Months-Change
Fundamentals
Return on Equity
83.45%
Trailing 12-Months
Asset Growth
287.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MiNK Therapeutics
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
INKT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call delivered several important operational and scientific advances: initiation and operationalization of a randomized Phase 2 ARDS study (including dosing in an active conflict zone), positive early clinical and mechanistic signals from run-in patients, launch of a paid international named patient access program (Brazil), and improved quarter-over-quarter loss metrics. However, early clinical data are limited and non-randomized, operating cash usage increased (cash modestly declined q/q to $8.8M), and enrollment/regulatory risks and funding needs remain. On balance, the call emphasized meaningful progress on execution and translational rationale while acknowledging remaining proof-of-concept and financing risks.View all INKT earnings summariesINKT Stock 12 Month Forecast
Average Price Target
$35.00
▲(207.56% Upside)
Technical Analysis
Ownership Overview
4.95% Insiders
1.40% Mutual Funds
<0.01% Other Institutional Investors
92.18% Public Companies and
Individual Investors